ES2300634T3 - Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina. - Google Patents

Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina. Download PDF

Info

Publication number
ES2300634T3
ES2300634T3 ES03782368T ES03782368T ES2300634T3 ES 2300634 T3 ES2300634 T3 ES 2300634T3 ES 03782368 T ES03782368 T ES 03782368T ES 03782368 T ES03782368 T ES 03782368T ES 2300634 T3 ES2300634 T3 ES 2300634T3
Authority
ES
Spain
Prior art keywords
prednisolone
cephalosporin
treatment
mastitis
cows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03782368T
Other languages
English (en)
Spanish (es)
Inventor
Gerardus Franciscus Cox. Peter
Joseph Antonius Clemens Maria Lohuis
Selma Marianne Hensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32524018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2300634(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2300634T3 publication Critical patent/ES2300634T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
ES03782368T 2002-12-16 2003-12-10 Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina. Expired - Lifetime ES2300634T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02080265 2002-12-16
EP02080265 2002-12-16

Publications (1)

Publication Number Publication Date
ES2300634T3 true ES2300634T3 (es) 2008-06-16

Family

ID=32524018

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03782368T Expired - Lifetime ES2300634T3 (es) 2002-12-16 2003-12-10 Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina.

Country Status (9)

Country Link
US (1) US7812009B2 (en:Method)
EP (1) EP1585497B1 (en:Method)
JP (2) JP5162080B2 (en:Method)
AT (1) ATE390124T1 (en:Method)
AU (1) AU2003290015A1 (en:Method)
CA (1) CA2508022C (en:Method)
DE (1) DE60320034T2 (en:Method)
ES (1) ES2300634T3 (en:Method)
WO (1) WO2004054538A1 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300634T3 (es) 2002-12-16 2008-06-16 Intervet International Bv Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina.
CN100368016C (zh) * 2005-04-01 2008-02-13 北京大北农农业科技研究院 治疗奶牛乳房炎的乳房灌注液及其制备方法
ES2346573T3 (es) * 2005-10-29 2010-10-18 Intervet International Bv Composiciones de cefquinoma y metodos para su uso.
WO2008025773A1 (en) * 2006-08-30 2008-03-06 Intervet International B.V. Pharmaceutical compositions comprising cefquinome
CN101148451A (zh) * 2007-05-16 2008-03-26 好维股份有限公司 一种口腔药物及口腔护理用品
WO2011074992A1 (en) * 2009-12-15 2011-06-23 Dec International Nz Limited Treatment composition and method
EP2510944A1 (en) * 2011-04-15 2012-10-17 National University of Ireland, Galway Treatment of bacterial infections
JP2014516950A (ja) * 2011-05-12 2014-07-17 インターベット インターナショナル ベー． フェー． 乳腺炎の治療
JP6271443B2 (ja) 2012-02-27 2018-01-31 バイエル・ニュージーランド・リミテッド 制御放出組成物およびその使用方法
EP3031464B1 (en) 2013-05-17 2020-04-01 Asahi Calpis Wellness Co., Ltd. Preventive or therapeutic agent for ruminant animal mastitis
JP2018525985A (ja) * 2015-07-29 2018-09-13 ジーナス ピーエルシー 乳生産量を改善するための雌牛の育種方法
ES2985441T3 (es) 2018-07-30 2024-11-05 Virbac Utilización novedosa de glucocorticoides para el tratamiento de infecciones microbianas epiteliales de un órgano que contiene fluidos con un orificio exterior natural en mamíferos
CN113209014A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效硫酸头孢喹肟混悬注射液及其制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU504840B2 (en) 1975-09-09 1979-11-01 Takeda Chemical Industries Ltd Medicinal compositions
JPS5234914A (en) * 1975-09-09 1977-03-17 Takeda Chem Ind Ltd Method and composition for preventing failing of milk secretion of live stocks
JPS52110816A (en) * 1976-03-15 1977-09-17 Takeda Chem Ind Ltd Medicines
ES2300634T3 (es) 2002-12-16 2008-06-16 Intervet International Bv Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina.

Also Published As

Publication number Publication date
US7812009B2 (en) 2010-10-12
WO2004054538A1 (en) 2004-07-01
AU2003290015A1 (en) 2004-07-09
JP2006514642A (ja) 2006-05-11
DE60320034T2 (de) 2009-05-14
JP5162080B2 (ja) 2013-03-13
ATE390124T1 (de) 2008-04-15
CA2508022C (en) 2012-01-31
JP2013035845A (ja) 2013-02-21
DE60320034D1 (de) 2008-05-08
EP1585497A1 (en) 2005-10-19
US20060058273A1 (en) 2006-03-16
EP1585497B1 (en) 2008-03-26
CA2508022A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
JP2013035845A (ja) 乳腺炎治療
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
JP2006528705A (ja) ウシおよびブタにおける感染を処置するための組成物
PL209943B1 (pl) Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy
JP2006528705A5 (en:Method)
US20140256661A1 (en) Pharmaceutical compositions for rectal administration
JPH11509871A (ja) カルバペネム系抗生物質、組成物及び調製方法
AU2012207698A1 (en) Injectable compositions for mastitis comprising an NSAID and an antibiotic in a non-aqueous solvent
BRPI0612447A2 (pt) composição antibiótica de dose fixa, processo para a preparação de um produto de combinação antibiótica de dose fixa, processo para a preparação de uma injeção lìquida e usos de pó seco para injeção e injeção lìquida
ES2074037T3 (es) Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales.
IE51846B1 (en) Pharmaceutical preparation for veterinary use and an appliance containing it
ES2311093T3 (es) Agentes para la terapia preventiva despues de un accidente cerebrovascular agudo.
ES2376432T3 (es) 8a-azalidas como agentes antimicrobianos veterinarios.
KR100190869B1 (ko) 아목시실린 및 클라부란산을 포함하여 구성되는 수의학적 조성물 및 그를 사용한 치료방법
EP0607122B1 (en) Veterinary treatment
KR102058133B1 (ko) 혼합제제 내 항생제 용해도를 향상시킬 수 있는 면역 증강용 조성물 및 이의 용도
EP0238207A1 (en) Bactericidal mixtures
WO2024079750A1 (en) Ready to use antibiotic solution for veterinary use
AU621459B2 (en) Compositions comprising baquiloprim and sulphadimethoxine
CN1771035A (zh) 包含大环内酯类t－细胞免疫调节剂或免疫抑制剂和抗菌剂的组合物
JP2018502155A (ja) 胃腸感染症を治療するための組成物及び方法
IE83642B1 (en) Veterinary treatment
KR20190065771A (ko) 덱스트란 또는 폴록사머를 포함하는 관절 질환 또는 결체조직 질환 치료용 조성물
JPH11501904A (ja) クラブラン酸の塩、バンコマイシンおよび１種またはそれ以上のベータ−ラクタム系抗生物質を含んでなる医薬処方